Advertisement

Topics

Companies Related to "Heart failure patients need sooner follow care" [Most Relevant Company Matches] RSS

04:12 EST 19th February 2019 | BioPortfolio

Here are the most relevant search results for "Heart failure patients need sooner follow care" found in our extensive corporate database of over 50,000 company records.

Showing "Heart failure patients need sooner follow care" Companies 1–25 of 9,400+

Extremely Relevant

The Heart Failure Society of America

Heart failure is a progressive condition in which the heart muscle becomes abnormal after damage from heart attack or high blood pressure and gradually loses its ability to pump enough blood to supply the body's needs. Many people are not aware they have heart failure because the symptoms are often mistaken for signs of getting older. Heart failure affects from 4.6 to 4.8 million individuals in th...


Heart Failure Society of America, Inc.

The Heart Failure Society of America, Inc. (HFSA) represents the first organized effort by heart failure experts from the Americas to provide a forum for all those interested in heart function, heart failure, and congestive heart failure (CHF) research and patient care. The Mission of HFSA is to: Promote research related to all aspects of heart failure and to provide a forum for presentation of ba...

Texas Heart Institute

The Texas Heart Institute (www.texasheart.org), founded by world-renowned cardiovascular surgeon Dr. Denton A. Cooley in 1962, is a nonprofit organization dedicated to reducing the devastating toll of cardiovascular disease through innovative and progressive programs in research, education and improved patient care. Together with its clinical partner, St. ...


Ancora Heart Inc.

Ancora Heart, Inc., based in Santa Clara, Calif., is dedicated to helping people with heart failure feel better and live longer. Ancora Heart developed the AccuCinch System, an investigational therapy designed to repair the enlarged left ventricle targeting the underlying cause of heart failure. The AccuCinch heart failure treatment was created to benefit ...

Ancora Heart, Inc.

Ancora Heart, Inc., based in Santa Clara, Calif., is dedicated to helping people with heart failure feel better and live longer. Ancora Heart developed the AccuCinch System, an investigational therapy designed to repair the enlarged left ventricle targeting the underlying cause of heart failure. The AccuCinch heart failure treatment was created to benefit ...

Sunshine Heart

Heart failure is a common condition in which the heart becomes unable to pump sufficient blood to meet the body's needs. Over five million people in the United States have heart failure and it results in over 300,000 deaths each year. Heart failure is a progressive condition and typically results from damage to the heart muscle arising from a heart attack or virus.

Terumo Heart Inc.

More than 22 million people suffer from heart failure worldwide with approximately one million new patients diagnosed annually. In the setting of an aging global population, heart failure is the number one reason for hospitalization. The most severely ill patients need heart transplants in order to recover. More than 8,000 people worldwide are on the list of eligible candidates for heart transpla...

3F Therapeutics, Inc

3F Therapeutics, Inc. was formed in late 1998 to develop, manufacture, and market innovative cardiovascular devices for patients with currently unmet clinical needs. The Company’s products are intended to significantly improve upon the performance of heart valves presently in the market and to address the resultant complications of patients with congestive heart failure. At present, over 260,000...

Relevant

SynCardia Systems, LLC

SynCardia Systems, LLC (www.syncardia.com) in Tucson, Ariz., is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. For people suffering from end-stage heart failure affecting both sides of the heart (biventricular failure), the SynCardia temporary Total Artificial Heart is used as a brid...

Miracor Medical Systems GmbH

Based in Vienna, Austria, privately held Miracor is commercializing a unique and potentially disruptive technology, PICSO®, for acute coronary syndrome (ACS), heart failure, and cardiac surgery patients. The Company’s objective is to establish PICSO® as the standard of care for heart attack patients, thereby improving their quality of life. The ...

DC Devices, Inc.

DC Devices, Inc. is dedicated to revolutionizing the treatment of heart failure with first-in-class structural heart devices. The company has developed the world’s first transcatheter device designed to treat diastolic heart failure (DHF), also known as heart failure with preserved ejection fraction (HFpEF). The InterAtrial Shunt Device (IASD™) S...

CircuLite®, Inc.

CircuLite is developing disruptive solutions to improve the treatment of chronic heart failure. The Company’s minimally invasive circulatory support systems are intended to work in conjunction with the heart to enhance clinical outcomes and improve quality of life for patients and their families. Synergy®, currently in a CE Mark clinical trial, fea...

ORQIS Medical Corporation

ORQIS Medical Corporation is a privately held, medical device company developing its discovery of a novel approach to treat the underlying mechanisms responsible for congestive heart failure. ORQIS Medical discovered that continuous aortic flow augmentation (CAFA), blood flow augmentation specifically in the descending aorta, may correct abnormal circulatory conditions associated with heart failur...

Acorn Cardiovascular

Acorn Cardiovascular™ is a privately held medical device company that was incorporated in 1996 and is located in St. Paul, Minnesota, USA. Mission: Acorn Cardiovascular develops innovative solutions to successfully treat patients with heart failure and restore hope for a better, longer life. Background: Heart failure (HF) is a condition that is caused by damage to the heart muscle, which re...

IPS HEART

IPS HEART is a privately-held biopharmaceutical company dedicated to addressing heart attack, heart failure and duchenne cardiomyopathy via next generation cellular therapy. IPS HEART was the first company to exclusively focus on induced pluripotent stem cells and heart disease. IPS HEART is a resident at Johnson & Johnson Innovation, JLABS at TMC in the T...

NitroMed

NitroMed, Inc. of Lexington, Massachusetts is a research-based emerging pharmaceutical company and the maker of BiDil, an orally administered medicine available in the United States for the treatment of heart failure in self-identified black patients. In this population, BiDil is indicated as an adjunct to current standard therapies such as ACE inhibitors and/or beta blockers. BiDil was approved b...

Celladon Corporation

Celladon Corporation, based in La Jolla, California, was launched in October 2004 as a privately held biotechnology company founded with the goal of becoming the leader in developing molecular therapies for the treatment of heart failure. The company’s products target the key enzyme deficiency in advanced heart failure, SERCA2a, which regulates calcium ...

Heart Care Centers of Illinois (HCCI)

Our mission at Heart Care Centers of Illinois (HCCI) is to provide the highest quality of care for our patients’ long term, comprehensive cardiovascular health. Our goal is to provide the most current, proven innovations in the areas of diagnostic cardiac examination, cardiovascular intervention and surgery, and heart-healthy therapeutic options. As a health care team owned and directed by p...

ARCA biopharma, Inc.

ARCA biopharma is dedicated to developing genetically targeted therapies for heart failure and other cardiovascular disease. The Company's lead product candidate, bucindolol hydrochloride, is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for heart failure. ARCA has identified common genetic variations that i...

Heart to Heart Hospice

Heart to Heart Hospice, founded in 2003, is one of the largest private providers of hospice care in the United States. Headquartered in Plano, TX, Heart to Heart Hospice provides a broad range of palliative and support care services to patients with life-limiting illnesses across 26 locations throughout Texas, Michigan and Indiana. Services provided includ...

CardioKine, Inc.

CardioKine is a specialty pharmaceutical company developing innovative compounds for the treatment and prevention of heart failure and related cardiovascular indications.Heart failure is one of the world’s fastest growing diseases, impacting all segments of society. It occurs when the heart becomes too weak to pump blood, leading to accumulation of fluids, shortness of breath and premature death...

Ventracor Limited

Ventracor is an international medical device company focused on commercialising the world’s leading ‘artificial heart’ device, the VentrAssist™ Left Ventricular Assist Device (LVAD). The VentrAssist™ is a new third generation implantable heart device primarily designed as an alternative to heart transplantation for people with cardiac failure. It may also be used for patients waiting for...

Celladon Corp.

Celladon Corp., based in La Jolla, Calif., was launched in October 2004 as a privately held biotechnology company with the goal of becoming the leader in developing molecular therapies for the treatment of heart failure. The company's products target calcium cycling and contractility deficit in heart muscle cells. In addition to MYDICAR®, Celladon is developing traditional small molecule activato...

Heart to Heart Hospice Foundation

Funded primarily through generous donations from families and friends of Heart to Heart Hospice patients, the Heart to Heart Hospice Foundation is a 501(c) (3) non-profit public charity that provides financial support for patients nearing end-of-life, their families and the greater community through various charitable programs. Each program includes financ...

The Heart Rhythm Society

The Heart Rhythm Society is the international leader in science, education and advocacy for cardiac arrhythmia professionals and patients, and the primary information resource on heart rhythm disorders. Its mission is to improve the care of patients by promoting research, education and optimal health care policies and standards. Incorporated in 1979 and ba...


More From BioPortfolio on "Heart failure patients need sooner follow care"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks